IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
1. IDEAYA submitted IND application for IDE892 to FDA. 2. Phase 1 trial for IDE892 in lung cancer starts Q4 2025. 3. IDE892 targets MTAP-deleted tumors with promising combination opportunities. 4. Synergistic effects expected with IDE397 in combination therapies. 5. 10-Year Anniversary R&D Day will review IDE892 preclinical profile soon.